550 related articles for article (PubMed ID: 29434366)
1. Potentiating prostate cancer immunotherapy with oncolytic viruses.
Lee P; Gujar S
Nat Rev Urol; 2018 Apr; 15(4):235-250. PubMed ID: 29434366
[TBL] [Abstract][Full Text] [Related]
2. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic viruses as engineering platforms for combination immunotherapy.
Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
[TBL] [Abstract][Full Text] [Related]
5. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
7. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
8. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for thoracic oncology gone viral.
Patel MR
Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
[TBL] [Abstract][Full Text] [Related]
11. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
12. Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.
Romano G; Marino IR
Drugs Today (Barc); 2019 Feb; 55(2):117-130. PubMed ID: 30816886
[TBL] [Abstract][Full Text] [Related]
13. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Workenhe ST; Verschoor ML; Mossman KL
Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
15. Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus.
Farrera-Sal M; Moya-Borrego L; Bazan-Peregrino M; Alemany R
Clin Cancer Res; 2021 Jun; 27(11):2979-2988. PubMed ID: 33526422
[TBL] [Abstract][Full Text] [Related]
16. SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
Gujar S; Bell J; Diallo JS
Cell; 2019 Feb; 176(5):1240-1240.e1. PubMed ID: 30794777
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Immunotherapy.
Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
[TBL] [Abstract][Full Text] [Related]
18. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
